Trends in bronchial hyperresponsiveness, respiratory symptoms and lung function among adults: West and East Germany  by RICHTER, K. et al.
Trends in bronchial hyperresponsiveness,
respiratory symptoms and lung function among
adults: West and East Germany
K. RICHTER*, J. HEINRICH{, R. A. JO¨RRES*, H. MAGNUSSEN*, H. E. WICHMANN{ FOR THE INGA
STUDY GROUP
*Krankenhaus Grosshansdorf, Zentrum fu¨r Pneumologie und Thoraxchirurgie, Grosshansdorf and
{GSF-Forschungszentrum fu¨r Umwelt und Gesundheit, Institut fu¨r Epidemiologie, Neuherberg, Germany
Previous studies have shown higher prevalences of bronchial hyperresponsiveness (BHR), respiratory symptoms
and atopic sensitization among adults in Western Germany than in Eastern Germany. One of the aims of the joint
project INGA (INdoor Factors and Genetics in Asthma) is to assess incidence, prevalence and trends for asthma,
BHR and atopic diseases over a time period of 11 years (1990–2001) in the former West (Hamburg) and East
Germany (Erfurt), with special reference to indoor exposure.
INGA was designed as a case-control study following a cross-sectional study performed from 1990 to 1992 within
the European Community Respiratory Health Survey (ECRHS). The database consisted of 1159 subjects in
Hamburg and 731 subjects in Erfurt from the ECRHS (age 20–44). In 1995–1996, 107 cases (diagnosed asthma,
positive specific serum IgE, positive skin prick or PD20FEV12?0mg methacholine at ECRHS) and 106 controls
(none of the previous findings) participated in Hamburg (115 cases and 109 controls in Erfurt). The methodology
was identical to the ECRHS and dose–response slopes (DRS) of the methacholine challenge were calculated as an
index of responsiveness.
In the control group, median values of DRS were 0?028%mg71 (1990–1992) and 0?044 (1995–1996) (P50?01) in
Erfurt. Corresponding values for Hamburg were 0?028 and 0?022 (NS). Corresponding values within the case
groups were 0?041 and 0?049 (NS) for Erfurt, and 0?069 and 0?052 (P50?05) for Hamburg.
Thus, 4 years after the first survey, we found an increased BHR in the Erfurt control group while the bronchial
responsiveness remained unchanged for the Hamburg group. These trends in BHR, which indicate the expected
converging tendency between East and West Germany, have to be confirmed within the next INGA-survey in 2000–
2001.
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One of the aims of the joint project INGA (INdoor factors
and Genetics in Asthma) is to assess incidence, prevalence
and trends for asthma, bronchial hyperresponsiveness and
atopic diseases over a time period of 11 years (1990–2001)
in former West and East Germany, with special respect to
indoor exposure. As part of the European Community
Respiratory Health Survey (ECRHS), a previous studyReceived 20 August 1999 and accepted in revised form 6 January
2000.
Correspondence should be addressed to: Kai Richter, MD,
Krankenhaus Grosshansdorf, Zentrum fu¨r Pneumologie und
Thoraxchirurgie, Wo¨hrendamm 80, D-22927 Grosshansdorf,
Germany. Fax: +49 4102 601 245. E-mail: k.richter@pulmor-
esearch.de
0954-6111/00/070668+10 $35?00/0clearly revealed that prevalences of respiratory symptoms,
atopic sensitization and bronchial responsiveness among
adults were higher in West Germany than in East Germany
(1). Nicolai et al. recently reported similar findings in adults
(2). Furthermore, the prevalence of current asthma and
hayfever among 9–11-year-old children was found to be
significantly higher in West Germany (3). The factors which
cause these striking dierences remain unclear, even though
several explanations have been proposed. Possible factors
could be exposure to dierent allergens or dierent
environmental factors, including outdoor and indoor
pollutants (4,5). If these factors really caused higher rates
in West Germany one might expect a tendency for
increased prevalence rates in the East when the exposure
factors in East Germany change towards the conditions met
in West Germany. The INGA study is the first study to
assess respiratory symptoms, lung function and bronchial# 2000 HARCOURT PUBLISHERS LTD
BHR TRENDS IN WEST AND EAST GERMANY 669responsiveness in relation to indoor allergen exposure in a
case-control design among adults in West and East
Germany. The aim of this paper is to analyse trends in
bronchial hyperresponsiveness, respiratory symptoms and
lung function among adults in the two German cities:
Erfurt (East Germany) and Hamburg (West Germany)
after German re-unification.
Material and methods
STUDY AREA
As part of the European Respiratory Health Survey
(ECRHS) the cities of Hamburg and Erfurt participated
in this study. The city of Hamburg is mainly a commercial
and administrative centre located in the north of former
West Germany, about 150 km from the North Sea and
50 km from the Baltic Sea. The population of Hamburg
consists of about 1?7 million people. The city of Erfurt is a
commercial centre with industrial parts located in a shallow
basin in the south-west of the former East Germany, with a
total population of about 0?21 million.
STUDY DESIGN
The study was designed as a case-control study following a
cross-sectional study performed from 1990 to 1992 within
the ECRHS. On the basis of the study results of the first
survey in 1990–1992 cases and controls were defined and
followed for an average period of 48?6 months. Every
subject willing to participate again attended the centre for a
detailed questionnaire including respiratory symptoms,
spirometry, methacholine or bronchodilator inhalation
tests, skin-prick testing and determination of total andTABLE 1. Description of database and subjects’ demography
Erfurt
Controls
Target population (n) 368
Randomly selected (n) 109
Questionnaire (%){ 100
Spirometry (%){ 95?4
Mch. Challenge (%){ 89?9
Age (years) 37?2
Gender
% male 60?6
% female 39?4
Smoking status
% never 52?3
% current 39?5
% ex 8?3
Higher educational level (%) 45?9
{% of randomly selected (n). **P50?01, *P50?05 as comparedspecific immunoglobulin E. The study was performed from
July 1995 to August 1996. Identical methodology was
followed in the two centres. The study protocol had been
approved by the local ethics committees and all subjects
gave their informed written consent.
SUBJECTS
The database consisted of 1159 subjects in Hamburg and
731 subjects in Erfurt who had participated within the
European Respiratory Health Survey (ECRHS). Cases for
the present study were defined as subjects fulfilling at least
one of the following four conditions according to the results
from the ECRHS (1990–1992): (i) asthma diagnosed by a
physician according to the long questionnaire of the
ECRHS (10), (ii) at least one positive specific serum IgE
(> 0?35 kU l71; CAP system, Pharmacia, Sweden) against
grass, birch, cat, Dermatophagoides pteronyssinus or
Cladosporium herbarum, (iii) at least one positive skin prick
test reaction (mean wheal diameter of at least 3 mm) against
the allergens mentioned above, (iv) PD20FEV12?0mg
methacholine or positive bronchodilator testing. The
subjects of the control group did not show anyone of these
conditions at the first survey. Based on these criteria, 107
cases and 106 controls were recruited from a random list of
538 cases and 621 controls in Hamburg. Similarly, in Erfurt
115 cases and 109 controls out of 363 cases and 368 controls
participated in the INGA study. Table 1 provides a
description of the database and subjects’ demography.
Subjects of the control group were significantly older in
Hamburg as compared to Erfurt. Furthermore, the
percentages of non-smokers were lower (P50?05) in
Hamburg in both the control and case group, and also
the percentage of ex-smokers was higher in Hamburg
within the control group (P50?01).Hamburg
Cases Controls Cases
363 621 538
115 106 107
100 100 100
93?0 100 100
77?4 96?2 96?3
37?9 40?2** 38?0
53?0 49?1 48?6
47?0 50?9 51?4
47?8 31?1** 32?7*
37?4 31?1 44?9
14?8 37?7** 22?4
43?5 38?7 37?4
to Erfurt.
670 K. RICHTER ET AL.METHACHOLINE CHALLENGE
Methacholine challenges were performed in all subjects
who were willing to participate and able to perform
adequate FEV1 and FVC manoeuvres (showing an FEV1
above 70% of mean predicted but not below 1?5 l). Subjects
who currently were on anti-asthmatic treatment were given
an appointment when they had taken their inhalers at least
4 h and their oral medication at least 8 h beforehand.
Challenges were performed using the Mefar MB3 dosimeter
and five individually calibrated dosimeters (Mefar Srl,
Bovezzo, Italy). The output of the dosimeter was checked
regularly throughout the study period. b2-agonists were
withheld for at least 4 h before each spirometry test and oral
asthma medication at least 8 h. After measuring baseline
values and the airway response to the diluent, increasing
concentrations of standard methacholine concentrations
(Methacholine chloride 171913; Synopharm Co., Barsbu¨t-
tel, Germany) were given. According to a history of
respiratory symptoms, a short protocol with four-fold
increases and a long protocol with two-fold increases in
methacholine concentrations were used. In either protocol,
subjects took a defined number of breaths (1–4), at intervals
of 6 sec starting from functional residual capacity, slowly
inhaling to total lung capacity, and holding their breath for
3 sec. The FEV1 manoeuvre was performed 2min after each
dose. Provocation was terminated when FEV1 had dropped
by 20% as compared to post-diluent values or after a
maximum cumulative dose of methacholine of 2?0mg.
PD20FEV1 was calculated as the cumulative dose of
methacholine necessary to decrease FEV1 by 20%. In
addition, according to Chinn et al. (6), the dose–response
slope g was calculated by fitting the line ‘fall in FEV1 =
d+g dose’ using the least-squares method. The dose–
response slope was considered as an index of responsive-
ness. Additionally the transformed dose–response slope
(TDRS) was calculated as TDRS=1/(slope+0?1). Further-
more a dose–response slope (DRS) of 0?05%mg71 was
considered as cut-o value to define mild BHR and a DRS
of 0?01 to define BHR in terms of DRS (7).
Any subject with a baseline FEV1 below 70% of the
mean predicted value received 200mg of salbutamol
by a metered dose inhaler. Spirometry was performed
10min after administration of the bronchodilator. A more
than 12% increase in FEV1 was considered a positive
response.
SPIROMETRY
Spirometric measurements were performed using pneumo-
tachograph-based electronic spirometers (Master Lab 4 in
the Hamburg Centre, and PSC-PC in the Erfurt Centre,
Jaeger Co., Wu¨rzburg, Germany) that met published
standards (8). Spirometry was performed according to the
ATS standards (9). To account for potential dierences
between the two devices, additional lung function measure-
ments were performed in a set of 44 volunteers with both
devices. We found a statistically significant dierence for
values of vital capacity (VC), forced expiratory volume in1 sec (FEV1) and peak expiratory flow (PEF); no significant
dierence was found in forced vital capacity (FVC).
Subsequently, the Pneumoscope device (PC) was consid-
ered as the standard device (independent variable) and the
Master Lab 4 device (ML) as a dependent variable. The
regression equations (standard errors are given in parenth-
esis) were:
(1) VCML=70?010 (0?088)+1?035 (0?019)*VCPC
(2) FEV1ML=0?057 (0?060)+1?037 (0?016)*FEV1PC
(3) FVCML=0?147 (0?077)+0?993 (0?016)*FVCPC
(4) PEFML=0?867 (0?242)+0?891 (0?025)*PEFPC
All mean values obtained by the Master Lab 4 device were
corrected according to these regression equations. This
procedure was considered to be statistically allowed as it
did refer to similar populations measured under identical
conditions.
In smokers, spirometry was performed at least 1 h after
the last cigarette had been smoked. Subjects had not had an
upper respiratory tract infection within the 3 weeks prior to
the visit in the laboratory.
QUESTIONNAIRE
The questionnaire used to assess respiratory symptoms such
as wheezing, chest tightness and shortness of breath within
the last 12 months, medical history, smoking, occupation
and social status had been developed according to the
validated long questionnaire with 71 items as used in the
ECRHS study (10). The validated German version of the
original ECRHS questionnaire was shortened to 40 items as
compared to the original version, without changing the
questions in their wording.
STATISTICAL ANALYSIS
Data were analysed using the PC statistical software
Statistica (Release 4?1). Multiple logistic regression analysis
was employed for the binary response variables BHR, DRS
 0?1 or 0?05. The distribution of DRS was skewed with
some negative values. Therefore, we used the reciprocal
transformation 1/(DRS+0?1) to obtain the transformed
dose–response slope (TDRS) (6). Due to the reciprocal
transformation, a lower value of TDRS represented a
higher methacholine responsiveness. Using this TDRS
analysis of trends for bronchial hyperresponsiveness were
performed by one-way within subjects (repeated measures)
analysis of covariance (ANCOVA).
Baseline lung function data were analysed using multiple
linear regression models to assess potential dierences
between Erfurt and Hamburg in control and case groups.
In all logistic and linear regression models, the eect of
smoking habits and educational level was studied using
categorical variables. In each model, gender, when appro-
priate, and age were carried as independent variables. Lung
function parameters were compared using Student’s t-test
for independent samples. Chi-squared tests were used to
compare prevalences between groups.
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RESULTS OF QUESTIONNAIRE
Results of the questionnaire are given in Table 2. In the
control group there was no statistically significant dier-
ence between the Erfurt and Hamburg groups regarding
respiratory symptoms, including wheezing, shortness of
breath and nighttime symptoms during the last 12 months.
When the results of the two surveys were compared within
the control group prevalences for wheezing and shortness
of breath had slightly increased in Erfurt between 1990/92
and 1995/96, but these dierences were not statistically
significant. In the case group, at the 1995/96 survey,
frequencies of respiratory symptoms were statistically
significantly dierent as compared to Erfurt, with higher
prevalences in Hamburg for wheezing and night-time
symptoms (P50?05). Furthermore, the case group in
Hamburg included nearly twice as many subjects who, at
the second survey, reported a doctor’s diagnosed asthma
(P50?05) and about five times more current use of asthma
medication as compared to Erfurt (P50?01). The use of
asthma medication increased significantly between 1990/92
and 1995/96 in Hamburg (P50?01). All other dierences in
prevalences between the two surveys were not statistically
significant dierent neither in the control nor in the case
groups in Hamburg and Erfurt.
BASELINE LUNG FUNCTION
Lung function parameters are given in Table 3. Mean
absolute values of FEV1 were significantly dierent between
Erfurt and Hamburg for the control groups (P50?01) but
not for the case groups. FEV1 (as % predicted) was higher
for the control group in Hamburg as compared to Erfurt
(109?1% and 102?0%, P50?01) In the case group there was
no significant dierence in FEV1 (as % predicted) between
Erfurt and Hamburg; the mean value of FEV1 % FVC was
lower in Hamburg than in Erfurt (81?7% and 83?9%,
P50?05). There were no significant dierences in FEV1
FEV1 (% predicted) and FEV1 % FVC between the control
group and the case group in Erfurt. In contrast, inTABLE 2. Results of the questionnaire (% prevalences)
Erfurt
Controls Cas
1990/92 95/96 1990/92
Diagnosis of asthma 0 0 4?3
Asthma medication 0 0 0?9
Wheezing 2?8 4?6 6?1
Shortness of breath 0?9 1?8 6?1
Nocturnal awakenings 4?6 0?9 4?3
*P50?05 1990/92 compared to 1995/96, Hamburg as comparedHamburg the case group had a significantly lower absolute
values of FEV1 and FEV1 (as % predicted) (P50?05). The
mean declines in FEV1 were significantly lower in Hamburg
as compared to Erfurt in the control and the case group.
Separate analyses for gender showed that these dierences
were only significant for men.
BRONCHIAL RESPONSIVENESS
Due to clinical contraindications and refusals by some
subjects, methacholine challenges were performed only in
85% of all subjects in Erfurt and 96% in Hamburg,
respectively. There were no significant dierences between
Hamburg and Erfurt for the survey performed in
1995–1996 regarding the months of the year when
methacholine challenges were performed. Compared to
the months of the year of the first survey in 1990–1992 there
was also no significant dierence for Hamburg or Erfurt.
Results of the methacholine challenges and bronchodilation
tests are given in Table 4. Mean values of TDRS (SEM) for
both centres and both studies are shown in Fig. 1 for the
control group. Mean values of TDRS indicated a sig-
nificantly higher degree of airway responsiveness for the
controls in Erfurt as compared to Hamburg. Compared to
the results of the ECRHS, there was a significant decrease
in TDRS corresponding to a higher degree of airway
hyperresponsiveness in Erfurt for the control group
(P=0.007, ANCOVA, adjusted for gender, age, smoking
status, educational level), whereas the bronchial respon-
siveness to methacholine did not change significantly
between the two studies for the subjects of the control
group in Hamburg. Mean values of TDRS 1995–1996 were
not statistically significant dierent between Erfurt and
Hamburg for the case groups. However, in Hamburg, the
TDRS increased significantly (P=0.009, ANCOVA), cor-
responding to a lower degree of airway hyperresponsiveness
for the subjects of the case group compared to the values
obtained during the ECRHS. The DRS for the case group
in Hamburg decreased significantly only in subjects with
asthma medication (P=0?03), but not in the subjects
without asthma medication (P=0?20). For the case group,Hamburg
es Controls Cases
95/96 1990/92 95/96 1990/92 95/96
5?2 0 0?9 9?4 15?0{
2?6 0 0?9 3?8 13?2*,{
6?1 4?7 4?8 10?4 15?0{
6?1 4?7 3?8 7?5 9?4
4?3 2?8 0?9 6?6 13?1{
to Erfurt 1995/96; {P50?05, {P50?01.
TABLE 3. Results of baseline lung function (mean values [95% CI])
Erfurt Hamburg
M F ~ M F ~
Controls (n) 65 39 104 52 54 106
Baseline lung function
FEV1 (l) 4?24 3?08 3?81 4?54** 3?30** 3?91**
[4?08–4?41] [2?94–3?22] [3?65–3?95] [4?38–4?71] [3?17–3?42] [3?75–4?07]
FEV1 (% predicted) 101?7 102?5 102?0 109?7** 108?5** 109?1**
FEV1 % FVC 83?5 84?9 84?0 81?2 83?0 82?1
FEV1580% predicted (n) 3 0 3 0 1 1
FEV1 1990–1992 4?57 3?34 4?11 4?68 3?47 4?06
[4?39–4?72] [3?19–3?48] [3?94–4?27] [4?52–4?83] [3?34–3?59] [3?91–4?21]
FEV1 % FVC 1990–1992 82?6 84?1 83?1 81?3 83?1 82?2
Decline FEV1 (ml)
{ 313 257 292 132** 170 151**
[250–376] [181–334] [244–341] [72–192] [117–222] [112–191]
Cases (n) 59 48 107 52 55 107
Baseline lung function
FEV1 (l) 4?16 2?99 3?64 4?25 3?05 3?64
[4?01–4?32] [2?84–3?14] [3?48–3?79] [4?07–4?43] [2?91–3?20] [3?48–3?80]
FEV1 (% predicted) 102?3 100?9 101?6 103?2 103?4 103?3
FEV1 % FVC 83?4 84?5 83?9 80?7* 82?7 81?7*
FEV1580% predicted (n) 3 3 6 2 6 8
FEV1 1990–1992 4?45 3?22 3?90 4?39 3?25 3?80
[4?30–4?61] [3?04–3?33] [3?73–4?06] [4?23–4?55] [3?12–3?37] [3?65–3?95]
FEV1 % FVC 1990–1992 81?5 82?6 82?0 79?8 82?8 81?4
Decline FEV1 (ml)
{ 297 211 259 133** 193 163**
[216–378] [134–287] [202–315] [55–210] [141–244] [118–209]
{ Dierence in FEV1 between 1990/92 and 1995/96.
**P50?01; *P50?05 as compared to Erfurt (adjusted for age, sex, smoking status).
672 K. RICHTER ET AL.the percentage of subjects with hyperresponsiveness to
methacholine decreased from 41?0% in the ECRHS to
27?4% (P=0?01) in the INGA study in Hamburg.
Corresponding values for Erfurt were 32?5% and 30?1%.
Odds-ratios for the dierent definitions of BHR compar-
ing Hamburg and Erfurt are presented in Table 5. The
percentage of subjects with BHR in the control group was
higher in Erfurt (13?3%) compared to Hamburg (6?9%) in
1995–1996. Corresponding values for the case group were
31?5% and 28?2% (NS). Furthermore, overall 8?1% (5?6%
in Erfurt and 10?3% in Hamburg) of all subjects who
showed bronchial hyperresponsiveness to methacholine
within the ECRHS, did not show bronchial hyperreactivity
within the INGA study. The percentage of subjects who
changed from normal responsiveness to hyperresponsive-
ness between the two studies was 7?1% (10?0% in Erfurt
and 5?9% in Hamburg). For comparison, 10?9% of all
subjects (10?6% in Erfurt and 11?3% in Hamburg) showed
constant bronchial hyperresponsiveness. Table 6 presents
the results for the analysis of the shift of BHR using a
multi-variate logistic regression model including dierent
factors. Univariate analysis showed that females had a
higher risk to show constant BHR as compared to malesubjects at both surveys, but when the baseline FEV1 was
taken into account, these dierences were abolished.
Subjects of the case group in Hamburg showed a significant
higher rate of reversion to normal BHR. There were no
other significant dierences between Hamburg and Erfurt
with regard to shift in BHR. Higher age and a non-smoking
status proved to be factors for a constant negative BHR at
both surveys. Reported respiratory symptoms were strongly
associated with a constant positive BHR (odds-ratio 3?2,
P50?01).
Discussion
Previous results from our follow-up study performed in
1994–1995, using a self-administered questionnaire which
was identical to the screening questionnaire of the ECRHS
from 1990–1992, indicated that the prevalence of atopic
diseases in East and West Germany might already converge
(11). Prevalence rates of asthma attacks, asthma medication
use, allergic rhinits and wheezing remained stable in
Hamburg but increased significantly in Erfurt, approaching
those of Hamburg. However, due to the fact that the
TABLE 4. Results of methacholine challenge including transformed dose response slope (TDRS, mean values [95% CI]).
Erfurt Hamburg
M F ~ M F ~
Controls (1995/96) (n) 61 37 98 50 52 102
BHR1 (% of n){ 5 (8?2) 8 (21?6) 13 (13?3) 2 (4?0) 5 (9?6) 7 (6?9)
DRS (%/mg){ 0?035 [70?040–0?213] 0?051 [0?005–0?653] 0?044 [70?040–0?653] 0?017 [70?022–0?214] 0?023 [70?005–1?61] 0?022 [70?005–1?61]
TDRS 7?45 [6?87–8?03] 6?49 [5?84–7?13] 7?07 [6?64–7?51] 8?57 [8?09–9?05] 7?64 [7?08–8?20] 8?10
1990/92 (n) 58 35 93 50 52 102
DRS (%/mg){ 0?027 [70?009–0?075] 0?035 [70?012–0?093] 0?028 [70?012–0?093] 0?024 [70?028–0?092] 0?032 [70?013–0?095] 0?028 [70?028–0?095]
TDRS 7?92 [7?60–8?24] 7?60 [7?12–8?06] 7?80 [7?53–8?06] 8?14 [7?70–8?58] 7?66 [7?24–8?08] 7?89 [7?59–8?19]
Cases 1995/96 (n) 57 36 93 51 55 106
BHR (% of n)* 13 (22?8) 15 (41?7) 28 (30?1) 7 (13?7) 22 (40?0) 29 (27?4)
DRS (%/mg){ 0?043 [70?035–1?05] 0?071 [70?002–7?53] 0?049 [70?035–7?53] 0?041 [0?001–2?80] 0?055 [70?046–18?86] 0?052 [70?046–18?8]
TDRS 6?71 [6?03–7?40] 5?11 [4?19–6?03] 6?08 [5?52–6?65] 6?62 [5?91–7?32] 6?18 [5?20–7?15] 6?39 [5?79–0?98]
1990/92 (n) 51 32 83 48 52 100
DRS (%/mg){ 0?036 [70?007–0?873] 0?109 [0?011–2?46] 0?041 [70?007–2?46] 0?046 [70?041–4?57] 0?115 [0–10?85] 0?069 [70?041–10?85]
TDRS 7?04 [6?51–7?59] 5?04 [4?11–5?97] 6?27 [5?75–6?79] 6?60 [5?75–7?45] 4?62 [3?75–5?49] 5?57 [4?94–6?20]
BHR (% of n)* 9 (17?6) 18 (56?3) 27 (32?5) 13 (27?1) 28 (53?9) 41 (41?0)
* Positive bronchodilator test or PD20 FEV12?0 mg.
{ Median values [range] given.
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FIG. 1. Transformed dose–response slopes for methacholine (TDRS) of control groups from (a) Hamburg and (b) Erfurt
within the ECRHS (1990–1992) and the INGA-study (1995–1996). Mean values+SEM are given. **P50?01.
TABLE 5. Comparison of the methacholine challenges between Hamburg and Erfurt. Odds-ratios{ [95% CI] Erfurt vs.
Hamburg have been calculated for the dierent conditions listed
Controls Cases
1990/92 1995/96 1990/92 1995/96
BHR * 3?13 [0?94–10?0] 0?86 [0?47–1?56] 1?18 [0?61–2?27]
Responsiveness
DRS0?1%/mg * 2?63 [0?90–7?69] 0?83 [0?45–1?54] 1?21 [0?61–2?38]
DRS0?05%/mg 1?27 [0?61–2?63] 5?88 [2?50–14?29] 0?69 [0?37–1?25] 0?93 [0?50–1?75]
{ Adjusted for sex, age, educational level, smoking status; DRS: dose-response-slope, BHR: positive bronchodilator test or
PD20 FEV12?0 mg.
* Odds-ratios not calculated because all subjects within the control group had negative BHR per definition in 1990–1992.
674 K. RICHTER ET AL.symptoms were self-reported, this converging tendency
might have been the result of an enhanced awareness
among the public and health care providers in East
Germany. Therefore, long-term follow-up measurements
of atopy (e.g. skin-prick testing or IgE-levels), lung function
and determination of bronchial responsiveness are needed.
Recently published results from von Mutius et al. showed
increasing prevalences of hayfever and atopy among
children in East Germany (12). However, in that group of
children (age 9–11 years) there was no significant change in
the prevalence of asthma, respiratory symptoms or
bronchial hyperresponsiveness.
Any interpretation of results from the INGA study has to
take into account that there have been drastic changes
towards Western lifestyle in Erfurt within the 5 years
between the ECRHS and INGA studies. It is a common
belief that environmental factors that may determine the
development of atopic sensitization, respiratory symptoms
and bronchial hyperresponsiveness, are important predo-
minantly in early life (13,14). From this point of view onemight expect that a change in environmental conditions
would not drastically influence the prevalence rates for
sensitization, symptoms or bronchial responsiveness in
adults (age 24–50 years).
There are only few data available about long-term
follow-up studies on bronchial hyperresponsiveness. Most
of these studies addressed children or adolescents (15,16).
Panhuysen et al. found that in a 25-year follow-up study in
adult patients with diagnosed asthma, about 21% of all
subjects did not show bronchial hyperresponsiveness at the
second test 25 years later (17). Our data, obtained over a
time period of 5 years, show a remission rate for bronchial
hyperresponsiveness of about 8% overall. The remission
rate was about twice as high in Hamburg as compared to
Erfurt. Conversely, the incidence rate for BHR was about
twice as high in Erfurt. These results might indicate a
converging tendency between Hamburg and Erfurt in terms
of bronchial responsiveness. The bronchial reactivity in
terms of TDRS decreased in the case group in Hamburg,
i.e. subjects were more likely to change from a positive
TABLE 6. Results of the multiple logistic regression analysis of shift in BHR between negative BHR (7) and positive BHR ()
from 1990/92 to 1995/96 for all subjects. Odds-ratios [95% CI] are given (for FEV1 baseline values means ratios [95% CI] are
given).
BHR 1990–92/ 1995–96
Factors entered in model 7/7 7/ /7 /
Female vs. male 0?35 [0?22–0?57]** 1?64 [0?75–3?55] 2?02 [0?91–4?50] 3?44 [1?49–7?90]**
Female vs. male 0?82 [0?44–1?55] 1?67 [0?51–5?43] 1?14 [0?31–4?26] 1?01 [0?44–2?33]
FEV1 baseline 2?12 [1?35–3?35]** 1?01 [0?55–1?85] 0?64 [0?26–1?55] 0?33 [0?19–0?59]**
Female vs. male 0?69 [0?34–1?42] 1?89 [0?64–5?60] 0?60 [0?14–2?66] 1?08 [0?48–2?46]
FEV1 baseline 2?01 [1?22–3?32]** 1?03 [0?57–1?86] 0?33 [0?10–1?06] 0?41 [0?19–0?86]*
Hamburg vs. Erfurt 1?02 [0?62–1?68] 0?49 [0?22–1?09] 2?90 [1?02–8?26]* 1?07 [0?56–2?03]
Age 30–34 vs. 24–29 1?24 [0?50–3?08] 1?56 [0?61–3?95] 0?15 [0?01–5?14] 0?89 [0?12–6?78]
Age 35–39 vs. 24–29 1?67 [0?78–3?58] 0?47 [0?14–1?53] 0?27 [0?06–1?25] 1?52 [0?38–6?02]
Age 40–50 vs. 24–29 2?15 [1?02–4?54]* 0?50 [0?17–1?41] 0?38 [0?12–1?25] 0?78 [0?18–3?44]
Smokers vs. non-smokers 0?53 [0?32–0?88]* 1?51 [0?70–3?24] 1?34 [0?50–1?99] 1?63 [0?91–2?94]
Symptoms vs. no symptoms 0?34 [0?17–0?67]** 2?10 [0?81–5?50] 0?57 [0?12–2?68] 3?20 [1?71–6?12]**
Medication vs. no medication 0?59 [0?14–2?40] – 0?13 [0?01–31?6] 3?30 [1?00–10?8]
*P50?05, **P50?01.
{One or more of the following symptoms: wheezing, shortness of breath, nocturnal awakenings.
BHR TRENDS IN WEST AND EAST GERMANY 675BHR to a negative BHR. In contrast, the prevalence of
doctor’s diagnosed asthma as reported in the questionnaire
and the use of asthma medication increased within the case
group in Hamburg (odds-ratio 2?9). This finding and the
decrease in bronchial hyperresponsiveness might be the
result of an improvement in asthma diagnosis and
treatment in West Germany. For comparison, bronchial
hyperresponsiveness and mild BHR remained unchanged
between the two surveys within the control group in
Hamburg.
The annual incidence rate of asthma was about 1?2% for
the case group in Hamburg as compared to about 0?2% for
the case group in Erfurt. Previous studies reported a mean
annual cumulative incidence of asthma in adults between
0?2 and 0?5% (18,19) for a general population sample. A
direct comparison of these incidence rates is not possible
due to the fact that results from the INGA study are based
on case-control cohorts, which are not representative of the
population in West and East Germany. Irrespective of the
dierences between Erfurt and Hamburg, out data confirm
that a greater airway calibre is associated with less BHR.
Previous studies have shown that bronchial hyperrespon-
siveness occurred more often in females than in males and
that these dierences were abolished when the lower
baseline FEV1 values were taken into account (7,20,21).
Moreover, our data are in line with previous observations
that respiratory symptoms are a major risk factor for BHR
(22,23).
Regarding the prevalences of respiratory symptoms there
were no unique trends in the control or case group from
Erfurt and in the control group from Hamburg. A
significant increase of respiratory symptoms was only
found for the case group in Hamburg. This is in line withthe higher prevalence of doctor’s diagnosed asthma and of
the use of asthma medication. These findings indicate that
at least for the case group, adults in West Germany are still
at higher risk to develop respiratory symptoms and
bronchial asthma. However, the fact that bronchial
hyperresponsiveness decreased overall within the case
group can only be explained by an eect of asthma
medication in the subset of treated subjects in this group.
The higher degree of bronchial responsiveness to
methacholine in the 1995–1996 survey as compared to the
1990–1992 survey which we found in the control group in
Erfurt, was not accompanied by a significant increase of
respiratory symptoms. There was only a weak trend for
increased prevalences of wheezing and shortness of breath.
However, the absolute number of subjects reporting
respiratory symptoms was low in all groups and the power
of statistical analyses was therefore limited. It was the
additional assessment of indoor exposure within the INGA
study (data not shown) which limited the total number of
subjects to be studied in Hamburg and Erfurt.
Magnitude of the decline in FEV1 as found in the case
and control groups in Hamburg was compatible with
findings of previous studies reporting that the decline of
FEV1 is at an average of 30ml year
71 (24) in healthy non-
smokers throughout life. The mean rate of decline amongst
smokers is approximately twice as high. It is known that
15–20% of smokers demonstrate an increased susceptibility
to tobacco smoke with a rate of decline of FEV1;
approximately twice the mean of all smokers (70–
120ml year71) (25). Peat et al. found a decline in FEV1 of
50ml year71 in non-smoking asthmatics as compared to
35ml year71 in healthy subjects (26). Regarding the decline
in FEV1 there were no significant dierences between
676 K. RICHTER ET AL.Hamburg and Erfurt in females. Male subjects however
showed a significantly higher rate of decline in FEV1 in
Erfurt. The reasons for these dierences remain unclear. At
least in the control group these findings might be partly
explained by the smoking status with less current smokers
and more ex-smokers in Hamburg, but after adjustment for
smoking status dierences were still significant. In the
control groups, baseline FEV1 was not dierent between
Erfurt and Hamburg at the first survey in 1990–1992.
Because of the strong association between airway calibre
and bronchial hyperresponsiveness, the significant decrease
in transformed dose response slopes which indicated higher
bronchial hyperresponsiveness in the control group in
Erfurt, was in line with the significantly lower baseline
FEV1 in Erfurt 1995–1996 as compared to Hamburg.
The decrease of the transformed dose response slope in
the control group in Erfurt is not likely to be due to changes
in methodology because an identical procedure of metha-
choline challenge has been used in both studies and there
was no significant dierence in the months of the year when
the two surveys were performed. Also, dierences in
participation rate were small in the control group and
therefore are unlikely to have biased the dierences in dose–
response-slopes for methacholine. This is supported by the
fact that there were also no dierences in age, gender, or
baseline lung function between participants and non-
participants.
In conclusion, our data provide objective evidence for the
hypothetical possible converging tendency between East
and West Germany in terms of bronchial responsiveness.
Nevertheless, the reported trends for bronchial hyper-
responsiveness should be confirmed within the next INGA-
survey which will be performed in the year 2000–2001.
It is policy of the joint project INGA to indicate that
further analyses of medical data (e.g. trends for atopy) and
the analysis of indoor exposure will be part of separate
publications.
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